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AbstrACt
Introduction There has been a growing awareness of 
the need for rigorously and transparent reported health 
research, to ensure the reproducibility of studies by future 
researchers. Health economic evaluations, the comparative 
analysis of alternative interventions in terms of their costs 
and consequences, have been promoted as an important 
tool to inform decision- making. The objective of this 
study will be to investigate the extent to which articles of 
economic evaluations of healthcare interventions indexed 
in MEDLINE incorporate research practices that promote 
transparency, openness and reproducibility.
Methods and analysis This is the study protocol for 
a cross- sectional comparative analysis. We registered 
the study protocol within the Open Science Framework ( 
osf. io/ gzaxr). We will evaluate a random sample of 600 
cost- effectiveness analysis publications, a specific form 
of health economic evaluations, indexed in MEDLINE 
during 2012 (n=200), 2019 (n=200) and 2022 (n=200). 
We will include published papers written in English 
reporting an incremental cost- effectiveness ratio in 
terms of costs per life years gained, quality- adjusted life 
years and/or disability- adjusted life years. Screening and 
selection of articles will be conducted by at least two 
researchers. Reproducible research practices, openness 
and transparency in each article will be extracted using a 
standardised data extraction form by multiple researchers, 
with a 33% random sample (n=200) extracted in duplicate. 
Information on general, methodological and reproducibility 
items will be reported, stratified by year, citation of the 
Consolidated Health Economic Evaluation Reporting 
Standards (CHEERS) statement and journal. Risk ratios 
with 95% CIs will be calculated to represent changes in 
reporting between 2012–2019 and 2019–2022.
Ethics and dissemination Due to the nature of the 
proposed study, no ethical approval will be required. 
All data will be deposited in a cross- disciplinary public 
repository. It is anticipated the study findings could be 
relevant to a variety of audiences. Study findings will be 
disseminated at scientific conferences and published in 
peer- reviewed journals.
IntroduCtIon
In recent years, there has been a growing 
awareness of the need for rigorous and 
transparent reporting of health research to 
ensure that studies can be reproduced.1–7 
The value of health research can be improved 
by increasing transparency and openness of 
the processes of research design, conduct, 
analysis and reporting.8 9 Sharing data and 
materials from health research studies has 
multiple positive effects within the research 
community: it is part of good publication 
practice in keeping the principles of Open 
Science; it allows for the conduct of additional 
analyses to further explore data and generate 
new hypotheses; it allows access to unpub-
lished data and it encourages reproducibility 
in research.10 Recognising the potential 
impact of open research culture, journals are 
increasingly supporting the use of reporting 
guidelines, as well as policies and technolo-
gies that help to improve transparency.11–13 
Scientists are increasingly encouraged to use 
strengths and limitations of this study
 ► To our knowledge, this will be the first attempt to 
examine the extent to which health economic evalu-
ations indexed in MEDLINE incorporate transparen-
cy, openness and reproducibility research practices.
 ► We will be able to collect data on a broad cross- 
section of health economic evaluations and will not 
restrict inclusion based on the medical specialty, 
disease condition or healthcare intervention.
 ► Study findings could be used to strengthen Open 
Science strategies and recommendations to in-
crease the value of health economic evaluations.
 ► The study may be limited by the inclusion of arti-
cles only catalogued in one database and written in 
English.
4300.7802.430. Protected by copyright.
 o
n
 February 26, 2020 at Erasm
us M
edical / X51
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-034463 on 13 February 2020. Downloaded from 
2 Catalá-López F, et al. BMJ Open 2020;10:e034463. doi:10.1136/bmjopen-2019-034463
Open access 
reproducible research practices, which allow others to 
perform direct replication of studies using the same data 
and analytic methods.14 15 Furthermore, research funders 
are changing their grant requirements including open 
data sharing.16 17
Health economic evaluations, which compare alterna-
tive interventions or programmes in terms of their costs 
and consequences,18 can help inform resource allocation 
decisions. A cost- effectiveness analysis, a specific form of 
economic evaluation that compares alternative options 
in terms of their costs and their health outcomes, is a 
valuable tool in health technology assessment processes. 
Cost- effectiveness analyses haves been promoted as an 
important research methodology for assessing value for 
money of healthcare interventions and an important 
source of information for making clinical and policy 
decisions.19 Decisions about the use of new interven-
tions in healthcare are often based on health economic 
evaluations. Efforts to increase transparent conduct 
and reporting of health economic evaluations have 
existed for many years.20–30 For example, the Consoli-
dated Health Economic Evaluation Reporting Standards 
(CHEERS) statement,30 first published in March 2013, 
provides recommendations for authors, peer reviewers 
and journal editors regarding how to prepare reports of 
health economic evaluations. The aim of CHEERS is to 
facilitate complete and transparent reporting of health 
economic evaluations and help more formal critical 
appraisal and interpretation. As a potential measure of 
impact,31 CHEERS has been cited over 1000 times in the 
Web of Science. However, little attention has been given 
to reproducibility practices such as sharing of study proto-
cols, data and analytic methods (which allow others to 
recreate the study findings) as part of health economic 
evaluation studies.22–25 29
Previous research has evaluated the impact of economic 
evaluation guidelines and the reporting quality of 
published articles. For example, Jefferson et al32 previously 
investigated whether publication (in August 1996) of the 
BMJ guidelines on peer review of economics submis-
sions made any difference to editorial and peer review 
processes, quality of submitted manuscripts and quality of 
published manuscripts in two high- impact factor medical 
journals (BMJ and The Lancet). In a sample of 105 articles 
on economics submissions, 27 (24.3%) were full health 
economic evaluations. Although Jefferson et al32 were 
not studying reproducibility, openness and transparency 
directly, they did undertake an assessment of the impact 
of a reporting guideline for health economic evalua-
tions. A 'before and after' assessment of implementation 
of the guideline was performed to assess how closely the 
reporting guidelines were followed. The authors found 
that the publication of the guidelines helped the editors 
improve the efficiency of the editorial process but had 
no impact on the reporting quality of health economic 
evaluations submitted or published.
The primary objective of this study will be to examine 
the extent to which articles of health economic evaluations 
of healthcare interventions indexed in Medline incorpo-
rate transparency, openness and reproducibility research 
practices. Secondary objectives will be to explore (1) how 
the reporting and reproducibility characteristics of health 
economic evaluations change between 2012 and 2022 and 
(2) whether the transparency and reproducibility prac-
tices have improved after the publication of the CHEERS 
statement in 2013.
MEthods And AnAlysIs
This is the study protocol for a cross- sectional, compar-
ative analysis. The present protocol has been registered 
within the Open Science Framework (registration iden-
tifier:  osf. io/ gzaxr). It is anticipated the study will be 
conducted during January 2020–December 2023.
Eligibility criteria
We will evaluate a random sample of 600 cost- effectiveness 
and cost- utility analyses of healthcare interventions, 
indexed in Medline during 2012 (n=200), 2019 (n=200) 
and 2022 (n=200), which focus on a healthcare inter-
vention in humans and reports an incremental cost- 
effectiveness ratio in terms of costs per life years gained, 
quality- adjusted life years or disability- adjusted life 
years. In particular, this analysis will focus on full health 
economic evaluations that measures health effects in 
terms of prolongation of life and/or health- related 
quality of life. We will select this specific form of health 
economic evaluations because many decision- makers and 
researchers have recommended this framework as the 
standard reference for cost- effectiveness in health and 
medicine.19 Publications of health economic evaluations 
will be limited to journal articles written in English with 
an abstract available.
We will exclude editorials, letters, narrative reviews, 
systematic reviews, meta- analysis, methodological articles, 
retracted publications and health economic evaluations 
that do not quantify health impacts in terms of life years 
gained, quality- adjusted life years or disability- adjusted 
life years.
searching
To provide a reliable summary of the literature, we will 
search Medline through PubMed (National Library 
of Medicine, Bethesda, Maryland, USA) for candidate 
studies throughout three cross- sectional, comparative 
time periods. First, we will search Medline- indexed arti-
cles in 2019 (‘reference year’) as it is the year closest 
to when the protocol for this study was drafted. In part 
two, we will search for articles indexed in 2012 and 2022, 
respectively, to further assess whether the transparency 
and reproducibility practices improved between 2012 (as 
it is 1 year before the publication of the CHEERS state-
ment in 201330) and 2022 (10 years after). The literature 
searches will be conducted by an experienced informa-
tion specialist. Our main literature search will be peer 
reviewed by a senior health information specialist using 
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the Peer Review of Electronic Search Strategies check-
list.33 The draft literature search strategy is based on a 
Medline search filter for economic evaluations34 and can 
be found in the online supplementary appendix 1.
screening
All titles and abstracts will be screened using liberal accel-
eration (where two reviewers need to independently 
exclude a record while only one reviewer needs to 
include a record). We will retrieve the full text of any 
citations meeting our eligibility criteria or for which eligi-
bility remains unclear. A form for screening full- text arti-
cles will be pilot tested on 50 articles. Subsequently, at 
least two reviewers will independently screen all full- text 
articles. Any discrepancies in screening full- text articles 
will be resolved via discussion or adjudication by a third 
reviewer if necessary.
data extraction
If more than 600 health economic evaluations are iden-
tified in the search, we will perform data extraction 
on a random sample of articles stratified by publica-
tion year (200 in 2022, 2019 and 2012, respectively). If 
fewer than 200 articles are identified in a given year (eg, 
2012), we will randomly select the sufficient number of 
studies published from the preceding year (eg, October–
December 2011) to match the number used in the study 
sample. We will not perform any sample size calculations 
since our study will evaluate multiple indicators that 
are considered all equally important, and they may vary 
substantially in the proportion to which they are satisfied 
by the included articles. However, 200 articles per year was 
assumed to be sufficient to capture potential differences.
Data in each article will be extracted using a stan-
dardised data extraction form by multiple researchers, 
with a 33% random sample (n=200) extracted in dupli-
cate. All data extractors will independently pilot test 
the form on 30 included studies to ensure consistency 
in interpretation of data items. Subsequently, data from 
each study will be independently extracted by one of 
several reviewers. Any discrepancies in the data extracted 
will be resolved via discussion or adjudication by a third 
researcher if necessary. Full articles and supplementary 
materials with data and analyses will be examined for 
general and methodological characteristics, statements 
of publicly available full protocols and data sets, conflicts 
of interest and funding disclosures. In particular, we will 
review the final versions of the articles available online.
The selection and wording of general, methodolog-
ical and reproducibility indicators will be influenced by 
recommendations from relevant articles on research 
transparency and reproducibility.4 5 7 8 29 35–41 The stan-
dardised data extraction form will include the following:
General characteristics
 ► Name of journal.
 ► Journal impact factor (according to the latest Journal 
Citation Report at the time of data extraction).
 ► Journal type (fully open access journal or subscription- 
based journal including those that may have open 
access content, eg, hybrid).
 ► Year of publication.
 ► Name, gender and country of corresponding author.
 ► Type of condition addressed by the economic eval-
uation (International Statistical Classification of 
Diseases and Related Health Problems, 10th Revision 
category).
 ► Type of interventions addressed (pharmacological, 
non- pharmacological, both) and the intervention to 
which it was compared (the ‘comparator’, eg, active 
alternative, usual care or placebo/do nothing) with 
adequate descriptions.40 41
 ► Type of economic evaluation (single- study- based 
economic evaluation or model- based economic 
evaluation).
 ► Study perspective (eg, society, healthcare system/
provider) and relate this to the costs being evaluated.
 ► Time horizon over which costs and outcomes are 
being evaluated.
 ► Discount rate used for costs and outcomes with 
rationale (when applicable).
 ► Health outcomes used as the measure of benefit 
(eg, life years gained, quality- adjusted life years or 
disability- adjusted life years) and their relevance for 
the type of analysis performed.
 ► Measurement of effectiveness (eg, for single- study- 
based estimates: a description of the design features 
of the single effectiveness study and why the single 
study was a sufficient source of clinical effectiveness; 
and for synthesis- based estimates: a description of the 
methods used for identification of included studies 
and synthesis of clinical effectiveness data).
 ► Estimate of resources and costs (including a descrip-
tion of approaches used to estimate resource use asso-
ciated with the alternative interventions and describe 
methods for valuing each resource item in terms of its 
unit costs).
 ► Discussion of all analytical methods supporting the 
evaluation (eg, methods for dealing with skewed, 
missing or censored data; extrapolation methods; 
methods for pooling data; methods for handling 
population heterogeneity and uncertainty such as 
subgroup analysis); choice of model and model cali-
bration and validation (when applicable).
 ► Results including number of incremental cost- 
effectiveness ratios (ICERs), sensitivity analyses, 
subgroup or heterogeneity analyses (eg, variations 
between subgroups of patients with different base-
line characteristics or other variability in effects), 
incremental costs and outcomes for base case anal-
ysis ICERs (defined as a qualitative representation 
of the index ICER for example, ‘more costs, more 
outcomes’, ‘less costs, more outcomes’, ‘less costs, 
comparable outcomes’), the cost- effectiveness ratio 
values (defined as quantitative representation of the 
base case analysis ICER), incremental costs (the ratio’s 
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numerator) and health effects (life years gained, 
quality- adjusted life years or both—the denominator 
of the ratio for base case analysis).
 ► Conclusions including favourable if the intervention 
clearly claims to be the preferred choice (eg, cited 
as ‘cost- effective’, ‘reduced costs’, ‘produced cost 
savings’‘ ‘an affordable option’, ‘value for money’), 
unfavourable if the final comments are negative 
(eg, the intervention is ‘unlikely to be cost- effective’, 
‘produced higher costs’, ‘is economically unattrac-
tive’ or ‘exceeded conventional thresholds of will-
ingness to pay’) and neutral or uncertain when the 
intervention of interest do not surpass the compar-
ator and/or when some uncertainty is expressed in 
the conclusions.
 ► Funding (eg, no statement, no funding, public, 
private, other, combination of public/private/other).
 ► Conflicts of interests (eg, no statement, statement no 
conflicts exist, statement conflicts exist).
Enablers for reproducibility, transparency and openness
 ► Citation and/or mention of CHEERS statement 
(eg, no citation/mention, citation/mention without 
reporting checklist, citation/mention with reporting 
checklist).
 ► Use of CHEERS appropriately (eg, when CHEERS 
was used as a reporting guideline to ensure a clear 
report of the study’s design, conduct and findings), 
inappropriately (eg, when CHEERS was used as a 
methodological tool to design or conduct health 
economic evaluations or as an assessment tool of 
methodological quality of publications reporting cost- 
effectiveness research) or in an unclear or neutral 
manner (eg, when use was neither appropriate nor 
inappropriate).31 42
 ► Open access or free availability in PubMed Central-
based on assignment of a specific identifier (yes, no).
 ► Protocol/registration mentioned (eg, no protocol, 
full protocol publicly available, full protocol publicly 
available and preregistered).
 ► Health economics analysis plan mentioned (eg, no 
analysis plan, indicated that analysis plan was avail-
able on request, full access to analysis plan along with 
research protocol).39
 ► Mention of raw data availability (eg, no data sharing, 
indicated that raw data were available on request, full 
access to raw data for reanalysis).
 ► Mention of access to analytic methods and algorithms 
(eg, ‘code’, ‘script’, ‘model’) used to perform analyses 
(eg, no access, indicated that analytic methods were 
available on request, full access to analytic methods 
for reanalysis).
 ► Type of data repository used, if appropriate including 
use of an open globally scoped repository (eg, Open 
Science Framework, Dryad, Mendeley, Zenodo), a 
journal repository (eg, additional file as webappendix 
or data paper) or other repository (eg, repository 
from a specific institution, project or nation).
 ► Data made available to recreate the index ICERs (base 
case).
 ► Data made available to recreate all core ICERs (base 
case and heterogeneity analysis).
 ► Data made available to recreate all ICERs (base case, 
heterogeneity analysis and uncertainty analysis) 
according to reporting standards.30 38
 ► Results have undergone rigorous independent repli-
cation and reproducibility checks (eg, whether the 
study claimed to be a replication effort in the abstracts 
and introductions)4 5: statement of novel findings (eg, 
the cost- effectiveness analysis claims that it presents 
some novel findings), statement of replication (eg, 
the cost- effectiveness analysis clearly claims that it is 
a replication effort trying to validate previous knowl-
edge or it is inferred that the cost- effectiveness is a 
replication trying to validate previous knowledge), 
statement of novel findings and replication (eg, the 
cost- effectiveness analysis claims to be both novel 
and to replicate previous findings), no statement on 
novelty or replication (eg, no statement or an unclear 
statement about whether the cost- effectiveness anal-
ysis presents a novel finding or replication).
data analysis
The analysis will be descriptive, with data summarised as 
frequency for categorical items or median and IQR for 
continuous items. We will characterise the indicators for 
the period 2012–2022. The proportion of general, meth-
odological and reproducibility indicators stratified by year 
will be reported, as well as citation use of the CHEERS 
statement and journal (eg, according to whether it is an 
original CHEERS endorsed journal or not). The draft 
list of original CHEERS endorsed journals can be found 
in the online supplementary appendix 2. A priori estab-
lished Fisher’s exact tests and risk ratios with 95% CIs will 
be calculated to represent changes in reporting between 
2012–2019 and 2019–2022. We will explore whether 
reproducible research practices are associated with the 
citation of the CHEERS statement. We will apply the p 
value <0.005 threshold for statistical significance with p 
values 0.05–0.005 suggestive.5 43 44
All analyses will be performed using Stata V.16 or higher 
(StataCorp LP).
updates and additional analyses
We plan to conduct a continual surveillance of the health 
economic literature, keeping evidence as up- to- date as 
possible. Iterations of the searches and review process 
will be repeated at regular intervals (eg, 3- year intervals 
after 2022) to continue to present timely and accurate 
findings. Reanalysis of the proposed reproducibility and 
transparency metrics and indicators may offer insight 
into progressive improvements in design, conduct and 
analysis of health economic evaluations over time.
Any (new) additional analysis examining potential asso-
ciations between general characteristics from extracted 
studies (eg, results including index ICER or funding 
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source) and enablers of reproducibility, transparency 
and openness (eg, mention of CHEERS statement, open 
access, protocol registration or mention of raw data) will 
be prospectively reported in a new specific (substudy) 
protocol, following standard methods described in this 
paper.
Patient and public involvement
No patients and/or public were involved in setting the 
research question nor they were involved in developing 
plans for design (or implementation) of this study 
protocol.
EthICs And dIssEMInAtIon
To the best of our knowledge, this cross- sectional anal-
ysis will be the first attempt to investigate the extent to 
which articles of cost- effectiveness of healthcare interven-
tions incorporate transparent, open and reproducible 
research practices. Without complete and transparent 
reporting of how a health economic evaluation is being 
designed and conducted, it is difficult for readers and 
potential knowledge users to assess its conduct and 
validity. Strengthening the reproducibility, openness 
and reporting of methods and results can maximise the 
impact of health economic evaluations by allowing more 
accurate interpretation and use of their findings. We 
anticipate the study could be relevant to a variety of audi-
ences including journal editors, peer reviewers, research 
authors, health technology assessment agencies, guide-
line developers, research funders, educators and other 
potential key stakeholders. Moreover, the study findings 
could further be used in discussions to strengthen Open 
Science to increase value and reduce waste from incom-
plete or unusable reports of health economic evaluations.
Any amendments made to this protocol when 
conducting the analyses will be outlined and reported in 
the final manuscript. Once completed, findings from this 
study will be published in peer- reviewed journals. All data 
underlying the findings reported in the final manuscript 
will be deposited in a cross- disciplinary public repository, 
such as the Open Science Framework (https:// osf. io/). 
In addition, when new data have become available, we 
will update the analysis and present the updated findings 
at a public repository (and we may also seek publication 
in a peer- reviewed journal).
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